EUCTR2005-002818-38-ITActive, not recruitingNot Applicable
ESPrES 500 - Evaluation of the safety profile of the new 500 mg film-coated tablet (FCT) formulation of boosted saquinavir (Invirase 500 mg) in HIV-1 infected patients
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- ROCHE
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Effectiveness and safety of the electroacupuncture for intractable neuropathic paiDiseases of the nervous systemKCT0003615Seoul National University Hospital40
Recruiting
Phase 1
A dose determining trial to assess the recommended dose of ES-3000 and ASTX727 for patients with MyelodysplasiaMyelodysplasiaCancer - Leukaemia - Acute leukaemiaACTRN12621001713886Australasian Leukaemia and Lymphoma Group32
Active, not recruiting
Phase 1
A PRELIMINARY EVALUATION OF THE SAFETY PROFILE OF TWENTY-FOUR HOUR INFUSION OF HUMAN RECOMBINANT ACTIVATED PROTEIN C (XIGRIS) EARLY IN SEVERE ACUTE PANCREATITIS. - XIG-AP 1Severe acute pancreatitis in man (with an APACHE II score of = 15) appears to carry a considerably higher risk of death when compared to general critical care patients with similar APACHE II scores. Current concepts of the pathophysiology of pancreatic necrosis suggest that disease progression is related to early activation of microvascular thrombotic pathways thus a theoretical case can be made for the use of activated protein C, early in the disease course of this illnessMedDRA version: 9.1 Level: LLT Classification code 10033647 Term: Pancreatitis acuteEUCTR2007-003635-23-GBCentral Manchester and Manchester Children's Hospitals NHS Trust30
Completed
Not Applicable
Evaluation of the safety and tolerability of the primary posterior capsulotomy during femtosecond laser-assisted cataract surgeryH26.9H26.4Cataract, unspecifiedAfter-cataractDRKS00010845niversitätsklinikum Knappschaftskrankenhaus Bochum GmbH Augenklinik41
Recruiting
Not Applicable
Safety and Technical Performance Evaluation of the Emboliner Embolic Protection Device: A New Zealand ExperienceTranscatheter aortic valve replacementEmbolic protectionCardiovascular - Other cardiovascular diseasesACTRN12622000473763Emboline, Inc.20